These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33171668)

  • 21. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence.
    Robalo-Cordeiro C; Campos P; Carvalho L; Borba A; Clemente S; Freitas S; Furtado S; Jesus JM; Leal C; Marques A; Melo N; Souto-Moura C; Neves S; Sousa V; Santos A; Morais A
    Rev Port Pneumol (2006); 2017; 23(5):287-293. PubMed ID: 28668400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
    Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
    Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nintedanib Reduces Neutrophil Chemotaxis via Activating GRK2 in Bleomycin-Induced Pulmonary Fibrosis.
    Chen WC; Chen NJ; Chen HP; Yu WK; Su VY; Chen H; Wu HH; Yang KY
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developments in the management of idiopathic pulmonary fibrosis.
    Drug Ther Bull; 2015 Jul; 53(7):78-81. PubMed ID: 26159700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice.
    Liu N; Song Y; Liu T; Wang H; Yu N; Ma H
    Clin Respir J; 2024 Jan; 18(1):e13731. PubMed ID: 38286745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluorofenidone attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice via restoring caveolin 1 expression and inhibiting mitogen-activated protein kinase signaling pathway.
    Meng J; Zou Y; Hu C; Zhu Y; Peng Z; Hu G; Wang Z; Tao L
    Shock; 2012 Nov; 38(5):567-73. PubMed ID: 23042199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CoQ10 enhances the efficacy of airway basal stem cell transplantation on bleomycin-induced idiopathic pulmonary fibrosis in mice.
    Liu H; Liu S; Jiang J; Zhang Y; Luo Y; Zhao J; Xu J; Xie Y; Liao W; Wang W; Nie Y; Li S; Deng W
    Respir Res; 2022 Feb; 23(1):39. PubMed ID: 35219329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caveolin-1-derived peptide limits development of pulmonary fibrosis.
    Marudamuthu AS; Bhandary YP; Fan L; Radhakrishnan V; MacKenzie B; Maier E; Shetty SK; Nagaraja MR; Gopu V; Tiwari N; Zhang Y; Watts AB; Williams RO; Criner GJ; Bolla S; Marchetti N; Idell S; Shetty S
    Sci Transl Med; 2019 Dec; 11(522):. PubMed ID: 31826982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Micellar Hyaluronidase and Spiperone as a Potential Treatment for Pulmonary Fibrosis.
    Skurikhin E; Madonov P; Pershina O; Ermakova N; Pakhomova A; Widera D; Pan E; Zhukova M; Sandrikina L; Artamonov A; Dygai A
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
    Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
    Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.
    Surolia R; Li FJ; Wang Z; Li H; Liu G; Zhou Y; Luckhardt T; Bae S; Liu RM; Rangarajan S; de Andrade J; Thannickal VJ; Antony VB
    JCI Insight; 2017 Jan; 2(2):e91377. PubMed ID: 28138565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models.
    Kim YS; Cha H; Kim HJ; Cho JM; Kim HR
    Molecules; 2019 Jul; 24(15):. PubMed ID: 31370295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.
    Selvaggio AS; Noble PW
    Annu Rev Med; 2016; 67():487-95. PubMed ID: 26565677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
    Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
    Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bleomycin Induces Drug Efflux in Lungs. A Pitfall for Pharmacological Studies of Pulmonary Fibrosis.
    Park JK; Coffey NJ; Bodine SP; Zawatsky CN; Jay L; Gahl WA; Kunos G; Gochuico BR; Malicdan MCV; Cinar R
    Am J Respir Cell Mol Biol; 2020 Feb; 62(2):178-190. PubMed ID: 31419911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of the pharmacokinetics and antifibrotic effects of nintedanib by intrapulmonary administration of a nintedanib-hydroxypropyl-γ-cyclodextrin inclusion complex in mice with bleomycin-induced pulmonary fibrosis.
    Togami K; Ogasawara A; Irie S; Iwata K; Yamaguchi K; Tada H; Chono S
    Eur J Pharm Biopharm; 2022 Mar; 172():203-212. PubMed ID: 35183716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis.
    Sari E; He C; Margaroli C
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Progress in randomized clinical trials of antifibrotic drug nintedanib and pirfenidone].
    Li YH; Ye Q
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2020 Jan; 38(1):62-65. PubMed ID: 32062902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.